Emerging approaches in molecular profiling affecting oncology drug discovery.
The purpose of this paper is to provide some perspectives on whether we are at a tipping point in understanding oncology and oncology drug discovery. It describes how model organisms have prepared us for more efficient drug discovery, lessons that are in use today. It provides examples of the emerging integration of biomarkers in patient care. It also details how over the next several years the processes of carrying out target identification and identifying responders to drugs will become more and more similar. In conclusion, a discussion is provided about who can do what to link the various components of this information-rich drug discovery process together.
Friend
S H
SH
Merck Research Laboratories, West Point, Pennsylvania 19486, USA.
D000818:Animals; D000970:Antineoplastic Agents / Q000302:isolation & purification / Q000494:pharmacology*; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor; D020869:Gene Expression Profiling; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D034741:RNA, Small Interfering / Q000235:genetics
D000970:Antineoplastic Agents; D034741:RNA, Small Interfering